{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:26:00Z","timestamp":1794324360432,"version":"4.9.0"},"reference-count":30,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SPI"],"published-print":{"date-parts":[[2016,12]]},"abstract":"\n OBJECT<\/jats:title>\n Systemic control of metastatic renal cell carcinoma (mRCC) has substantially improved with the development of VEGF, mTOR, and checkpoint inhibitors. The current first-line standard of care is a VEGF tyrosine kinase inhibitor (TKI). In preclinical models, TKIs potentiate the response to radiotherapy. Such improved efficacy may prolong the time to salvage therapies, including whole-brain radiotherapy or second-line systemic therapy.<\/jats:p>\n As the prevalence of mRCC has increased, the utilization of spine stereotactic radiosurgery (SRS) has also increased. However, clinical outcomes following concurrent treatment with SRS and TKIs remain largely undefined. The purpose of this investigation was to determine the safety and efficacy of TKIs when delivered concurrently with SRS. The authors hypothesized that first-line TKIs delivered concurrently with SRS significantly increase local control compared with SRS alone or TKIs alone, without increased toxicity.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n A retrospective cohort study of patients undergoing spine SRS for mRCC was conducted. Patients undergoing SRS were divided into 4 cohorts: those receiving concurrent first-line TKI therapy (A), systemic therapy\u2013na\u00efve patients (B), and patients who were undergoing SRS with (C) or without (D) concurrent TKI treatment after failure of first-line therapy. A negative control cohort (E) was also included, consisting of patients with spinal metastases managed with TKIs alone. The primary outcome was 12-month local failure, defined as any in-field radiographic progression. Multivariate competing risks regression was used to determine the independent effect of concurrent first-line TKI therapy upon local failure.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n One hundred patients who underwent 151 spine SRS treatments (232 vertebral levels) were included. At the time of SRS, 46% were receiving concurrent TKI therapy. In each SRS cohort, the median prescription dose was 16 Gy in 1 fraction. Patients in Cohort A had the highest burden of epidural disease (96%, p < 0.01).<\/jats:p>\n At 12 months, the cumulative incidence of local failure was 4% in Cohort A, compared with 19%\u201327% in Cohorts B\u2013D and 57% in Cohort E (p < 0.01). Multivariate competing risks regression demonstrated that concurrent first-line TKI treatment (Cohort A) was independently associated with a local control benefit (HR 0.21, p = 0.04). In contrast, patients treated with TKIs alone (Cohort E) experienced an increased rate of local failure (HR 2.43, p = 0.03). No toxicities of Grade 3 or greater occurred following SRS with concurrent TKI treatment, and the incidence of post-SRS vertebral fracture (overall 21%) and pain flare (overall 17%) were similar across cohorts.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n The prognosis for patients with mRCC has significantly improved with TKIs. The present investigation suggests a local control benefit with the addition of concurrent first-line TKI therapy to spine SRS. These results have implications in the oligometastatic setting and support a body of preclinical radiobiological research.<\/jats:p>\n <\/jats:sec>","DOI":"10.3171\/2016.4.spine16229","type":"journal-article","created":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T10:02:34Z","timestamp":1467972154000},"page":"766-774","source":"Crossref","is-referenced-by-count":58,"title":["Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma"],"prefix":"10.3171","volume":"25","author":[{"given":"Jacob A.","family":"Miller","sequence":"first","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine,\u00a0"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan H.","family":"Balagamwala","sequence":"additional","affiliation":[{"name":"Departments of Radiation Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilyana","family":"Angelov","sequence":"additional","affiliation":[{"name":"Neurosurgery and"},{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Suh","sequence":"additional","affiliation":[{"name":"Departments of Radiation Oncology,"},{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Rini","sequence":"additional","affiliation":[{"name":"Medical Oncology, Taussig Cancer Institute; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Medical Oncology, Taussig Cancer Institute; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet","family":"Ahluwalia","sequence":"additional","affiliation":[{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio"},{"name":"Medical Oncology, Taussig Cancer Institute; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Chao","sequence":"additional","affiliation":[{"name":"Departments of Radiation Oncology,"},{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-spine16229","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11060-015-1862-6","article-title":"Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1-3 newly diagnosed brain metastases","volume":"124","author":"Ahluwalia","year":"2015"},{"key":"b2-spine16229","series-title":"Onkologie","first-page":"674","article-title":"Radiation recall dermatitis induced by pazopanib","volume":"36","author":"Azad","year":"2013"},{"key":"b3-spine16229","series-title":"J Neurosurg Spine","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3171\/2012.8.SPINE12303","article-title":"Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma","volume":"17","author":"Balagamwala","year":"2012"},{"key":"b4-spine16229","series-title":"Technol Cancer Res Treat","doi-asserted-by":"publisher","first-page":"3","DOI":"10.7785\/tcrt.2012.500229","article-title":"Principles of radiobiology of stereotactic radiosurgery and clinical applications in the central nervous system","volume":"11","author":"Balagamwala","year":"2012"},{"key":"b5-spine16229","series-title":"Ann Pharmacother","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1345\/aph.1M469","article-title":"Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy","volume":"44","author":"Basille","year":"2010"},{"key":"b6-spine16229","series-title":"J Neurosurg Spine","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3171\/SPI-07\/08\/151","article-title":"Phase I\/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure","volume":"7","author":"Chang","year":"2007"},{"key":"b7-spine16229","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1016\/j.ijrobp.2012.01.080","article-title":"Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery","volume":"83","author":"Cox","year":"2012"},{"key":"b8-spine16229","series-title":"World J Surg Oncol","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1477-7819-10-167","article-title":"Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma","volume":"10","author":"Inoue","year":"2012"},{"issue":"Suppl","key":"b9-spine16229","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"S568","DOI":"10.1016\/j.ijrobp.2013.06.1508","article-title":"Incidence and risk factors for pain flare following spine radiosurgery","volume":"87","author":"Jung","year":"2013"},{"key":"b10-spine16229","series-title":"Target Oncol","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11523-013-0280-y","article-title":"Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial","volume":"9","author":"Kao","year":"2014"},{"key":"b11-spine16229","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ijrobp.2011.05.067","article-title":"Marginal recurrence requiring salvage radiotherapy after stereotactic body radiotherapy for spinal metastases","volume":"83","author":"Koyfman","year":"2012"},{"key":"b12-spine16229","series-title":"World J Urol","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00345-004-0466-0","article-title":"Novel approaches in the therapy of metastatic renal cell carcinoma","volume":"23","author":"Lam","year":"2005"},{"key":"b13-spine16229","series-title":"Nature","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/28412","article-title":"Combined effects of angiostatin and ionizing radiation in antitumour therapy","volume":"394","author":"Mauceri","year":"1998"},{"key":"b14-spine16229","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma","volume":"335","author":"Motzer","year":"1996"},{"key":"b15-spine16229","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013"},{"key":"b16-spine16229","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009"},{"key":"b17-spine16229","series-title":"N Engl J Med","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007"},{"key":"b18-spine16229","series-title":"Surg Today","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s00595-012-0475-3","article-title":"Gastro-pleuro-pericardial fistula following combined radiation and chemotherapy for lung metastases from renal cell carcinoma: report of a case","volume":"43","author":"Neri","year":"2013"},{"key":"b19-spine16229","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.ijrobp.2009.03.062","article-title":"Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy","volume":"76","author":"Nguyen","year":"2010"},{"key":"b20-spine16229","series-title":"Pract Radiat Oncol","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.prro.2013.05.001","article-title":"RTOG 0631 Phase 2\/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: Phase 2 results","volume":"4","author":"Ryu","year":"2014"},{"key":"b21-spine16229","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/j.ijrobp.2011.06.271","article-title":"RTOG 0631 Phase II\/III study of image-guided stereotactic radiosurgery for localized (1-3) spine metastases: Phase II results","volume":"81","author":"Ryu","year":"2011"},{"key":"b22-spine16229","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.2013.50.1411","article-title":"Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score","volume":"31","author":"Sahgal","year":"2013"},{"key":"b23-spine16229","series-title":"Cancer Res","first-page":"4009","article-title":"SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models","volume":"63","author":"Schueneman","year":"2003"},{"key":"b24-spine16229","series-title":"BJU Int","first-page":"673","article-title":"Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma","volume":"108","author":"Staehler","year":"2011"},{"key":"b25-spine16229","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1200\/JCO.2012.47.7455","article-title":"Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months","volume":"31","author":"Straka","year":"2013"},{"key":"b26-spine16229","series-title":"J Neurosurg Spine","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3171\/2014.7.SPINE13895","article-title":"Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture","volume":"21","author":"Thibault","year":"2014"},{"key":"b27-spine16229","series-title":"Clin Genitourin Cancer","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.clgc.2013.04.012","article-title":"Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium","volume":"11","author":"Vickers","year":"2013"},{"key":"b28-spine16229","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ijrobp.2014.05.034","article-title":"A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma","volume":"90","author":"Wuthrick","year":"2014"},{"key":"b29-spine16229","series-title":"BMC Cancer","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2407-13-3","article-title":"Early onset recall pneumonitis during targeted therapy with sunitinib","volume":"13","author":"Yuasa","year":"2013"},{"key":"b30-spine16229","series-title":"Cancer Biol Ther","doi-asserted-by":"publisher","first-page":"401","DOI":"10.4161\/cbt.19291","article-title":"Inhibition of STAT1 sensitizes renal cell carcinoma cells to radiotherapy and chemotherapy","volume":"13","author":"Zhu","year":"2012"}],"container-title":["Journal of Neurosurgery: Spine"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-spine\/25\/6\/article-p766.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-spine\/25\/6\/article-p766.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-spine\/25\/6\/article-p766.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T18:06:44Z","timestamp":1681582004000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-spine\/25\/6\/article-p766.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":30,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.3171\/2016.4.spine16229","relation":{},"ISSN":["1547-5654"],"issn-type":[{"value":"1547-5654","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}